SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,348.93. The last known price of BNB is 702.2705794 USD and is down -0.19 over the last 24 hours. It is currently trading on 3523 active market(s) with $1,103,086,320.06 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Reports of a massive Binance security breach and multibillion-dollar crypto theft dominate discussion, raising fears about customer fund safety, withdrawals, and the exchanges financial resilience. Some traders suspect an inside job or question why BNBs decline has been limited, while others view the selloff as a broader crypto-market reaction.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of Innodata layoffs in India and the Philippines, with termination notices citing a ramp-down in business assignments, have fueled concern that a major customer project may be shrinking. Traders are divided between viewing the cuts as efficiency or staffing changes and fearing lost revenue; the client impact remains unconfirmed, with many looking to the next earnings update for clarity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Traders are focused on Ocular Therapeutixs planned AXPAXLI NDA submission for wet AMD, with some watching for FDA acceptance as the key step toward a review timeline. Views are divided on whether the filing will lift the stock or is already priced in, amid continued share-price weakness and debate over competitive and commercial risks.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is drawing attention amid a sharp, volatile pullback in Micron and memory-chip stocks, with traders debating whether the selloff reflects broader semiconductor weakness and concerns about AI demand or temporary liquidation. Many are buying dips in hopes of a rebound, while others warn that the leveraged fund could fall further.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October delivery report is the main focus: deliveries reached a monthly record, led in part by rapid overseas growth, but traders question whether the pace can meet ambitious fourth-quarter expectations. The growth story is tempered by concerns about vehicle margins and profitability, alongside frustration over the stocks prolonged decline.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing therapy for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS and sparked a sharp selloff. Traders disagree on the threat: some emphasize PAPZIMEOSs first-mover, full-approval and commercial advantages, while others see the rivals treatment approach as a potential challenge to its sales.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Discussion centers on BCRXs prolonged share-price weakness despite ORLADEYO revenue growth, with investors watching quarterly results for evidence that the business and managements strategy can regain confidence. Bulls cite commercial cash flow, the expanded ORLADEYO pellet option and future navenibart and Netherton data; skeptics point to HAE competition, dilution and the long wait for pipeline catalysts.

iShares Trust - iShares 7-10 Year Treasury Bond ETF

iShares 7-10 Year Treasury Bond ETF

Concerns about persistent inflation, a hawkish Fed outlook, and rising Treasury yields dominate the discussion, with traders debating whether intermediate bonds can recover or face further pressure. Some also worry that AI companies borrowing could compete with Treasury issuance for investor capital, while others see a buying opportunity if yields ease.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

BDR Pharmaceuticals lawsuit challenging the FDAs exclusivity extension for Phathoms Voquezna is the main overhang, as an unfavorable outcome could permit earlier generic competition. Traders are split between viewing the challenge as unlikely to succeed and worrying that prolonged legal uncertainty will weigh on the stock, alongside concerns about sales growth, debt and royalties.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulfs AI/HPC data-center pivot and long-term Anthropic-backed lease are driving discussion, with traders viewing Anthropic-related disclosures as validation of demand for independent compute and power infrastructure. The bullish case points to future contracts and short-squeeze potential, while skeptics focus on financing, debt, execution risk, and weakness across AI infrastructure stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HOOD An overreaction to a mixed report that is mostly positive tbh. The slowdown in crypto trading is a cyclical phenomenon that we’ve seen before. However where it previously was an existential threat to Robinhood’s business model, they have sufficiently diversified into a financial ecosystem that can now weather such storms and still churn out profits at a healthy clip. 

I’ll be looking to add on this short term hiccup as the long term growth story is not only intact but improving. Buy the dips and your future self will thank you.

Ronald Gaygan

Ryan "EVgo" M.

Terry

James

SMH_SPCX_QQQ

Jason

joe blow

Horza

Jack

SkipBreakfast

Patrick

Willie Cicci

StockTwits for iOS

Robinhood Markets Inc

 An overreaction to a mixed report that is mostly positive tbh. The slowdown in crypto trading is a cyclical phenomenon that we’ve seen before. However where it previously was an existential threat to Robinhood’s business model, they have sufficiently diversified into a financial ecosystem that can now weather such storms and still churn out profits at a healthy clip. 

I’ll be looking to add on this short term hiccup as the long term growth story is not only intact but improving. Buy the dips and your future self will thank you.